![](/images/graphics-bg.png)
Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study
المؤلفون المشاركون
Halimeh, Susan
Bidlingmaier, Christoph
Heller, Christine
Gutsche, Sven
Holzhauer, Susanne
Kenet, Gili
Kurnik, Karin
Manner, Daniela
Iorio, Alfonso
Nowak-Göttl, Ulrike
المصدر
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2013-10-01
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Among the discussed risk factors for high-titre inhibitor (HRI) development in patients with hemophilia A (HA) are high dose FVIII replacement therapy and use of recombinant FVIII concentrates (rFVIII).
The aim of this study was to evaluate the aforementioned risk factors for HRI development in children with hemophilia A ≤2%.
About 288 ascertained PUPs (Israel and Germany) were followed after initial HA diagnosis over 200 exposure days.
Inhibitor-free survival, hazard ratios (HR), and 95% confidence intervals (CIs) were calculated.
Adjustment was performed for factor VIII concentrates, median single dose over the first three months of treatment, first FVIII administration before the age of three months, presence of risk HA gene mutations, “intensive treatment moments” and “year of birth” (proxy for different treatment periods).
HRI occurred in 71/288 children (24.7%).
In multivariate analysis adjusted for “year of birth”, underlying risk gene mutations (HR/CI: 2.37/1.40–3.99), FVIII dose, measured per one IU increase per kgbw (HR/CI: 1.05/1.04–1.07), and first FVIII administration before the age of three months showed a significant impact on HR development.
The risk of HRI development was similar for recombinant or plasmatic FVIII products.
Children at risk should be treated with carefully calculated lower dose regimens, adapted to individual bleeding situations.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Halimeh, Susan& Bidlingmaier, Christoph& Heller, Christine& Gutsche, Sven& Holzhauer, Susanne& Kenet, Gili…[et al.]. 2013. Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study. BioMed Research International،Vol. 2013, no. 2013, pp.1-7.
https://search.emarefa.net/detail/BIM-1005358
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Halimeh, Susan…[et al.]. Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study. BioMed Research International No. 2013 (2013), pp.1-7.
https://search.emarefa.net/detail/BIM-1005358
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Halimeh, Susan& Bidlingmaier, Christoph& Heller, Christine& Gutsche, Sven& Holzhauer, Susanne& Kenet, Gili…[et al.]. Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study. BioMed Research International. 2013. Vol. 2013, no. 2013, pp.1-7.
https://search.emarefa.net/detail/BIM-1005358
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1005358
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)